HUP0300942A2 - Ellenanyag és/vagy kemokin konstrukciók és használatuk immunológiai rendellenességekben - Google Patents
Ellenanyag és/vagy kemokin konstrukciók és használatuk immunológiai rendellenességekbenInfo
- Publication number
- HUP0300942A2 HUP0300942A2 HU0300942A HUP0300942A HUP0300942A2 HU P0300942 A2 HUP0300942 A2 HU P0300942A2 HU 0300942 A HU0300942 A HU 0300942A HU P0300942 A HUP0300942 A HU P0300942A HU P0300942 A2 HUP0300942 A2 HU P0300942A2
- Authority
- HU
- Hungary
- Prior art keywords
- chemokine
- constructs
- antibody
- cells
- infected
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title abstract 8
- 108010012236 Chemokines Proteins 0.000 title abstract 8
- 208000026278 immune system disease Diseases 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 abstract 4
- 102000009410 Chemokine receptor Human genes 0.000 abstract 3
- 108050000299 Chemokine receptor Proteins 0.000 abstract 3
- 241000713711 Primate lentivirus group Species 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 102000001327 Chemokine CCL5 Human genes 0.000 abstract 1
- 108010055166 Chemokine CCL5 Proteins 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
Abstract
A találmány tárgya egy kemokin receptorhoz kötődő ellenanyag és/vagykemokin konstrukció használata, azzal a céllal, hogy olyan gyógyászatikészítményt készítsenek, amivel eliminálni lehet azokat a sejteket,amik látensen fertőzöttek egy főemlős immundeficiencia vírussal. Atalálmány tárgya továbbá egy kemokin receptorhoz kötődő ellenanyagés/vagy kemokin konstrukció használata gyulladásos vesebetegségek,gyulladásos bélbetegségek, szklerózis multiplex, bőrbetegségek,diabetesz vagy transzplantátum kilökődés kezelésére, megelőzéséreés/vagy enyhítésére alkalmas gyógyászati készítmény előállítására. Atalálmány tárgyát képezik továbbá ellenanyag-konstrukciók és/vagykemokinkonstrukciók, pontosabban olyan konstrukciók, amikben azemlített ellenanyag konstrukció tartalmaz egy kötőhelyet a kemokin 5-ös receptorhoz, és egy CD3 kötőhelyet, valamint az említettkemokinkonstrukció tartalmaz RANTES-t és egy toxint. A találmánybanismertetik továbbá az említett ellenanyag- vagy kemokinkonstrukciókatkódoló polinukleotidokat, valamint az említett nukleinsav molekulákattartalmazó vektorokat és gazdaszervezeteket. A találmány tárgyátképezik továbbá az említett ellenanyag-konstrukciókat,kemokinkonstrukciókat, polinukleotidokat, vektorokat és/vagygazdaszervezeteket tartalmazó készítmények. Az említett készítményelőnyösen gyógyászati készítmény. Ismertetik továbbá az ellenanyag-konstrukciók, a kemokinkonstrukciók, a polinukleotidok, agazdaszervezetek és/vagy a vektorok használatát gyógyászati készítményelőállítására, amivel kezelni, megelőzni és/vagy enyhíteni lehet egyimmunológiai rendellenességet, vagy eliminálni lehet látensenfertőzött sejteket, amely említett sejtek a főemlős immundeficienciavírussal, azaz például HIV-1-gyel vannak fertőzve. A találmány tárgyatovábbá eljárás egy immunológiai rendellenesség kezelésére,megelőzésére és/vagy enyhítésére, vagy olyan sejtek eliminálására,amelyek látensen fertőzöttek egy főemlős immundeficiencia vírussal.Emellett a találmány tárgya egy kit, ami a találmány szerintivegyületeket tartalmazza. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00119694 | 2000-09-08 | ||
| US09/948,004 US6723538B2 (en) | 1999-03-11 | 2001-09-05 | Bispecific antibody and chemokine receptor constructs |
| PCT/EP2001/010433 WO2002020615A2 (en) | 2000-09-08 | 2001-09-10 | Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0300942A2 true HUP0300942A2 (hu) | 2003-09-29 |
Family
ID=32842663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300942A HUP0300942A2 (hu) | 2000-09-08 | 2001-09-10 | Ellenanyag és/vagy kemokin konstrukciók és használatuk immunológiai rendellenességekben |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1317284A2 (hu) |
| JP (1) | JP2004508036A (hu) |
| AU (1) | AU2002212225A1 (hu) |
| CA (1) | CA2421842A1 (hu) |
| HU (1) | HUP0300942A2 (hu) |
| NO (1) | NO20031070L (hu) |
| PL (1) | PL366062A1 (hu) |
| RU (1) | RU2252786C2 (hu) |
| WO (1) | WO2002020615A2 (hu) |
| ZA (1) | ZA200301890B (hu) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002360073A1 (en) * | 2001-12-21 | 2003-07-09 | Micromet Ag | Mono-and dual chemokine/cytokine constructs |
| EP2336179A1 (en) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Stabilized single domain antibodies |
| EP1937311A2 (en) | 2005-09-30 | 2008-07-02 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for modulating immune tolerance |
| NZ575163A (en) | 2006-08-28 | 2011-12-22 | Jolla Inst Allergy Immunolog | Antagonistic human light-specific human monoclonal antibodies |
| AR065369A1 (es) | 2007-02-19 | 2009-06-03 | Novartis Ag | Derivados de ciclohexil - amida del acido aril- carboxilico |
| SG10201407388XA (en) | 2007-08-29 | 2015-01-29 | Sanofi Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
| DK2585089T3 (en) * | 2010-06-28 | 2016-12-12 | Universitätsklinikum Freiburg | CCL18 blockade of signaling through CCR6 as a therapeutic option in fibrotic diseases and cancer |
| EP4303236A3 (en) | 2010-11-30 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| CA2943943C (en) | 2014-04-07 | 2023-01-10 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| SG11201609370QA (en) | 2014-05-13 | 2016-12-29 | Chugai Pharmaceutical Co Ltd | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| US11660340B2 (en) | 2015-11-18 | 2023-05-30 | Chugai Seiyaku Kabushiki Kaisha | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function |
| US11649293B2 (en) | 2015-11-18 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for enhancing humoral immune response |
| WO2017210749A1 (en) * | 2016-06-10 | 2017-12-14 | Adelaide Research & Innovation Pty Ltd | Methods and products for treating autoimmune diseases |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| EP4090348A4 (en) * | 2020-01-13 | 2024-05-15 | The Regents of The University of California | METHODS FOR TREATING VIRAL INFECTIONS |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000004926A2 (en) * | 1998-07-22 | 2000-02-03 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
| ATE286074T1 (de) * | 1999-03-11 | 2005-01-15 | Micromet Ag | Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten |
-
2001
- 2001-09-10 CA CA002421842A patent/CA2421842A1/en not_active Abandoned
- 2001-09-10 WO PCT/EP2001/010433 patent/WO2002020615A2/en active Application Filing
- 2001-09-10 RU RU2003108885/15A patent/RU2252786C2/ru not_active IP Right Cessation
- 2001-09-10 HU HU0300942A patent/HUP0300942A2/hu unknown
- 2001-09-10 JP JP2002525234A patent/JP2004508036A/ja not_active Withdrawn
- 2001-09-10 PL PL01366062A patent/PL366062A1/xx not_active Application Discontinuation
- 2001-09-10 AU AU2002212225A patent/AU2002212225A1/en not_active Abandoned
- 2001-09-10 EP EP01980364A patent/EP1317284A2/en not_active Ceased
-
2003
- 2003-03-07 ZA ZA200301890A patent/ZA200301890B/en unknown
- 2003-03-07 NO NO20031070A patent/NO20031070L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200301890B (en) | 2004-03-16 |
| EP1317284A2 (en) | 2003-06-11 |
| NO20031070L (no) | 2003-05-06 |
| WO2002020615A3 (en) | 2002-07-25 |
| JP2004508036A (ja) | 2004-03-18 |
| CA2421842A1 (en) | 2002-03-14 |
| RU2252786C2 (ru) | 2005-05-27 |
| WO2002020615A2 (en) | 2002-03-14 |
| AU2002212225A1 (en) | 2002-03-22 |
| NO20031070D0 (no) | 2003-03-07 |
| PL366062A1 (en) | 2005-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300942A2 (hu) | Ellenanyag és/vagy kemokin konstrukciók és használatuk immunológiai rendellenességekben | |
| SE0104340D0 (sv) | New compounds | |
| EP2341063A3 (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease | |
| ATE330967T1 (de) | An her2 bindende peptidverbindungen | |
| RU2011152816A (ru) | ПРИМЕНЕНИЕ АНТИТЕЛА ПРОТИВ Tau pS422 ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ГОЛОВНОГО МОЗГА | |
| RU2007108067A (ru) | Антагонистические антитела к il-17 | |
| MXPA05011110A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. | |
| SE0104331D0 (sv) | Novel compounds | |
| RU2003108885A (ru) | Конструкции антител и хемокинов и их применение при иммунологических нарушениях | |
| ATE361359T1 (de) | Funktion und aktivität des viralen proteins r (vpr) | |
| DE60028248T2 (de) | Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen | |
| WO2004067549A2 (de) | Peptide gegen kälteunverträglichkeit hervorrufende autoantikörper und ihre verwendung | |
| RU94046144A (ru) | Замещенные (арилалкиламинобензил) аминопропионамидные производные, их применение, способы их получения, фармкомпозиция | |
| WO1994023035A2 (de) | REKOMBINANTES LIESCHGRASPOLLENALLERGEN Phl p II | |
| CA2250433A1 (en) | Human dnase ii | |
| CA2210871A1 (en) | Human dnase i variants | |
| RU2103991C1 (ru) | Средство для лечения стрептококковых заболеваний | |
| WO2003096020A3 (en) | Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8) | |
| RU2104015C1 (ru) | Средство для лечения заболеваний, вызванных коли-инфекцией | |
| JPS58103383A (ja) | 新タンニン | |
| EA199800941A1 (ru) | Терапевтические средства, содержащие кислородные анион-радикалы и/или продукты их последующего превращения и расщепления, и их применение для лечения болезни паркинсона | |
| Ryden | Studies on interactions between staphylococcal cells and some connective tissue components. | |
| UA85995C2 (ru) | Химерическое антитело, которое специфически связывается с человеческим il-6, и фармацевтическая композиция, которая его содержит | |
| RU2000121049A (ru) | Антигены neisseria meningitidis | |
| BR9710824A (pt) | Processo para produção da proteìna gp160 recombinante e da proteina gp160 recombinante do vìrus da imunodeficiência humana. |